Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China ...
For adults and adolescents with moderate-to-severe plaque psoriasis, selective blockade of the interleukin-23 receptor with ...
Linerixibat decreased serum interleukin-31 levels in patients with primary biliary in cholangitis after 24 weeks, which may ...
In this video, Nancy S. Reau, MD, FAASLD, AGAF, discusses the impact of linerixibat on potential mediators of pruritus in patients with primary biliary cholangitis from the phase 3 double-blind, ...
Researchers created a dissolvable microneedle patch that delivers IL-4 directly to damaged heart tissue, jump-starting repair ...
Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind ...
A study out of the University of North Carolina at Chapel Hill has unveiled new insights into the inflammatory processes behind periodontitis, a common and debilitating gum disease. Research conducted ...
Background Eosinophilic oesophagitis (EoE) is a chronic allergic disease characterised by oesophageal epithelial remodelling, barrier dysfunction and inflammation. The transcription factor forkhead ...
To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2025 Financial Results Call. A ...
Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing ...
Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback